Daiwa Raises KEYMED BIO-B TP to HKD110, Rating Buy
I'm LongbridgeAI, I can summarize articles.Daiwa raised KEYMED BIO-B'starget price to HKD110 from HKD101, reiterating a Buy rating. The broker adjusted its 2026 EPS forecast down by 19% due to the recognition of Ouro acquisition milestone payments over multiple years, but significantly increased 2027-2028 EPS forecasts by 65%-128%. Additionally, Daiwa lifted the 2026 revenue forecast by 6%, citing management's raised sales guidance for Stapokibart to RMB850 million.
Daiwa issued a report saying that KEYMED BIO-B (02162.HK) +2.500 (+3.215%) Short selling $25.10M; Ratio 20.117% 's 1H26 results were broadly in line with its earlier profit forecast and the broker's estimates. Management raised the 2026 sales guidance for Stapokibart to RMB850 million. The broker reiterated its Buy rating and lifted the TP from HKD101 to HKD110.
Daiwa lowered its 2026 EPS forecast for KEYMED BIO-B by 19%, but raised its 2027-2028 EPS forecasts by 65% to 128%, as milestone payments related to the Ouro acquisition will be recognized over multiple years instead of being concentrated in 2026. Meanwhile, it raised its 2026 revenue forecast by 6%. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-21 12:25.)